Royfman R

No ORCID on file · 1 paper in corpus · active 2021
2021
Journal of Cancer ·doi:10.7150/jca.49406

While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years. Treatment options are less effective at each recurrence highlighting the need for novel maintenance therapies. PolyADP-ribose p…